The Morning Blend

Actions

The Morning Blend: New Hope for Prostate Cancer Patients

FDA Approves Innovative, Targeted Treatment
Videos
NOVARTIS GAINS FDA APPROVAL
Posted at 3:18 PM, Apr 21, 2022
and last updated 2022-04-21 16:00:32-04

MD, Medical Director, Oliver Sartor, and Clinical Trial Participant, Vanue B. Lacour Jr. explain the importance of this FDA approval, what it means for people with mCRPC, how Pluvicto differs from Standard of Care (SOC), and when and how it is delivered to patients.

Paid for by Novartis. For more information, visit Pluvicto.com.